Trials / NCT05874310
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
Recruiting now Early Phase 1 Gene therapy
- Sponsor
- Frontera Therapeutics
- Treatment
- FT-002
- Gene
- RPGR
- Conditions
- X-Linked Retinitis Pigmentosa
- Ages
- 8 Years to 45 Years
- Enrollment
- 18 participants
- Started
- 2023-02-01
- Main results expected
- 2023-10-31
- Results posted
- Not yet
- Record last updated
- 2023-05-24
What the study is testing
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
Where it runs
China (2)
- Peking Union Medical College Hospital, Beijing, Beijing Municipality (recruiting now)
- Eye & ENT hospital of Fudan university, Shanghai, Shanghai Municipality (recruiting now)